Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
Opus Genetics announced that the FDA accepted its OPGx-LCA5 program into the Rare Disease Evidence Principles (RDEP) initiative. This program supports therapies for ultra-rare diseases affecting fewer than 1,000 patients in the U.S. and enables early collaboration on trial design and evidence generation.
Key figures
- Drug Name
- OPGx-LCA5
- Phase Of Trial
- Phase 1/2
- Us patient population
- <1000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.